Pilot Study of Imaging Human Skin With High-Speed Spectrally Encoded Confocal Microscopy
Launched by MASSACHUSETTS GENERAL HOSPITAL · Sep 22, 2020
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
SECM provides an order of magnitude faster imaging speed than conventional confocal microscopy devices. The investigators have previously utilized the SECM technology for imaging large area of human esophagus in vivo. They have also developed endoscopic capsule devices which have been used to safely image over 60 human subjects, healthy volunteers and subjects with eosinophilic esophagitis, using SECM technology, rapidly.
When used for skin imaging, SECM can provide real-time three-dimensional confocal imaging and significantly reduce the imaging time. While SECM has been successfully used...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy adults
- • 18 years of age or older
- • Capable of giving informed consent
- • Pigmented lesions (such as moles) present on the forearm
- Exclusion Criteria:
- • Unable to provide consent
- • Open cuts/sores on the skin, skin infection, or any contagious skin condition
- • Pregnant women (according to subject)
- • Employees under the direct supervision of the investigator
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Guillermo Tearney, M.D, PhD.
Principal Investigator
Massachusetts General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials